Affandi Omar1,4*, Salina Abdul Rahman1, Fatimah Diana Amin Nordin1, Nur Azian Aziz2, Balqis Kamarudin1, Lock Hock Ngu3, Huey Yin Leong3, Mohd Shihabuddin Ahmad Noorden4, Julaina Abdul Jalil1
1. Inborn Errors of Metabolism & Genetics Unit, Institute for Medical Research (IMR), National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia
2. Institute of Medical Molecular Biotechnology, Sg Buloh Campus, Universiti Teknologi Mara (UiTM), Sungai Buloh, Malaysia
3. Department of Genetics, Kuala Lumpur Hospital, Ministry of Health Malaysia, Kuala Lumpur, Malaysia
4. Faculty of Pharmacy, Puncak Alam Campus, Universiti Teknologi Mara (UiTM), Puncak Alam, Malaysia
*Corresponding author: Affandi Omar.
ABSTRACT
INTRODUCTION: Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disease caused by deficiency in the iduronate-2-sulphatase (IDS) enzyme, leading to the accumulation of glycosaminoglycans (GAGs) in multiple tissues and this causes progressive multisystemic disease. Current treatment for MPS II, mainly enzyme replacement therapy, can improve somatic symptoms but are limited by high costs, the need for frequent intravenous infusions, and inability to effectively address neurological involvement due to poor bioavailability and inability to cross the blood-brain barrier. These challenges have led to interest in pharmacological chaperone therapy, which uses small molecules to help restore IDS activity and may allow for easier oral treatment.
OBJECTIVE(S): This study aimed to evaluate the effect of heparin octadecasaccharide (HO18) on IDS activity in MPS II patients.
MATERIALS & METHODS: Cultured fibroblasts from MPS II patients (n=8) treated with 15 µM of HO18 for 96 hours followed by measurement of IDS activity as primary outcome and glycosaminoglycans (GAGs) as secondary outcome to assess the chaperone's effect on enzyme function in vitro.
RESULTS: Out of eight patients, HO18 significantly enhanced IDS activity (≥2-fold, p < 0.05) in MPS II fibroblasts from three patients with the following mutations: p.(Leu259Pro), p.(Arg110Lys) and an IDS recombination mutation. However, a corresponding reduction in GAGs concentrations (p < 0.05) was not consistently observed.
CONCLUSION: In conclusion, HO18 showed promise as a pharmacological chaperone for iduronate-2-sulphatase in a minority of MPS II patients. These findings warrant further investigation to elucidate the mechanisms underlying the variable response and to identify patients most likely to benefit from this therapy.
KEYWORDS: Glycosaminoglycans, Iduronate-2-sulphatase, In vitro Study, Mucopolysaccharidosis Type II, Pharmacological Chaperone Therapy


